Clik here to view.
Joseph R. Bertino, MD – ASCO 2012 – HemOnc Today Video Perspective
Updated results from a phase 3 trial that compared bendamustine plus rituximab to CHOP chemotherapy plus rituximab in over 500 patients with indolent and mantle cell lymphoma were presented at ASCO...
View ArticleClik here to view.
Adam Brufsky, MD, PhD – ASCO 2012 – HemOnc Today Video Perspective
Adam Brufksy, MD, PhD, discusses results from the phase 3 EMILIA trial. The findings, presented at the ASCO plenary session, could present a new treatment option for women with HER-2–positive tumors...
View ArticleClik here to view.
Edith A. Perez, MD – ASCO 2012 – HemOnc Today Video Perspective
Edith A. Perez, MD, discusses the clinical impact of the FinHER trial and its findings, which explore the prognostic value of lymphocyte infiltration in patients with ER-negative and HER-2–negative...
View ArticleClik here to view.
Fadi Braiteh, MD – ASCO 2012 – HemOnc Today Video Perspective
Fadi Braiteh, MD, discusses the phase 3 study that found the addition of bevacizumab to standard chemotherapy during second-line treatment extended OS for patients with metastatic colorectal cancer...
View ArticleClik here to view.
Donald L. Trump, MD – ASCO 2012 – HemOnc Today Video Perspective
Donald L. Trump, MD, discusses the significance of the abiraterone study, which found that the addition of abiraterone during 6 months of hormonal therapy prior to surgery eliminated or nearly...
View ArticleClik here to view.
Richard Goldberg, MD – ASCO 2012 – HemOnc Today Video Perspective
Richard Goldberg, MD, discusses some of the trending topics at the ASCO 2012 Annual Meeting, including the use of targeted agents for late-stage colorectal cancer and increased recognition of...
View ArticleClik here to view.
Barbara Burtness, MD – ASCO 2012 – HemOnc Today Video Perspective
Barbara Burtness, MD, discusses the dose-escalation phase I study from Juneko E. Grilley-Olson and colleagues. According to the findings, the investigational ALK inhibitor LDK378 showed substantial...
View ArticleClik here to view.
Paul K. Paik, MD – ASCO 2012 – HemOnc Today Video Perspective
Paul K. Paik, MD, discusses the recent study from Ramaswamy Govindan, MD, and colleagues. The researchers identified squamous cell carcinoma of the lung as a distinct molecular subtype of lung cancer...
View ArticleClik here to view.
Edith A. Perez, MD – ASCO 2012 – HemOnc Today Video Perspective
The EMILIA trial presented by Karen L. Blackwell, MD and colleagues was a significant topic for discussion at ASCO 2012, as patients who received the experimental antibody-drug conjugate experienced...
View ArticleClik here to view.
Donald L. Trump, MD – ASCO 2012
Results of a Phase 3 trial were presented by Hussain and colleagues in a plenary session at the 2012 ASCO Annual Meeting. In this video perspective, Donald L. Trump, MD, offers his opinions on the...
View ArticleClik here to view.
Kanti R. Rai, MD – ASCO 2012 – HemOnc Today Video Perspective
Kanti R. Rai, MD, comments on the many compelling posters presented at ASCO with regard to the treatment of patients with relapsed refractory CLL. These include the use of PTK inhibitors, GS-1101, and...
View ArticleClik here to view.
Miguel A. Villalona, MD – ASCO 2012 – HemOnc Today Video Perspective
In the LUX-Lung 3 trial, James Chih-Hsin Yang, MD, PhD and colleagues observed that treatment with afatinib significantly extended PFS vs. standard chemotherapy treatment in patients with advanced...
View ArticleClik here to view.
Barbara Burtness, MD – ASCO 2012 – HemOnc Today Video Perspective
Barbara Burtness, MD, discusses the clinical impact of the DeCIDE and PARADIGM trials and their influence in the treatment of patients with head and neck cancers who were poor responders to...
View Article
